Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3830)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 15, 2022 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527 [PMID: 36160737 DOI: 10.4251/wjgo.v14.i8.1510] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v14/i8/1510.htm |
| Number | Citing Articles |
| 1 |
Dimitrios S. Karagiannakis. Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma. Cancers 2023; 16(1): 51 doi: 10.3390/cancers16010051
|
| 2 |
Kazuhiro Nouso, Shohei Shiota, Rio Fujita, Akiko Wakuta, Kazuya Kariyama, Atsushi Hiraoka, Masanori Atsukawa, Joji Tani, Toshifumi Tada, Yu Matsuo, Shinichiro Nakamura, Kazuto Tajiri, Masaki Kaibori, Masashi Hirooka, Ei Itobayashi, Satoru Kakizaki, Atsushi Naganuma, Toru Ishikawa, Takeshi Hatanaka, Shinya Fukunishi, Kunihiko Tsuji, Kazuhito Kawata, Koichi Takaguchi, Akemi Tsutsui, Chikara Ogawa, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Takashi Kumada. Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma. Liver Cancer International 2023; 4(3-4): 101 doi: 10.1002/lci2.74
|
| 3 |
Teiji Kuzuya, Naoto Kawabe, Mizuki Ariga, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Takeshi Takahara, Yutaro Kato, Yoshiki Hirooka. Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status. Cancers 2023; 15(11): 2952 doi: 10.3390/cancers15112952
|
| 4 |
Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda. Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma. Hepatology Research 2024; 54(4): 403 doi: 10.1111/hepr.13986
|